NCT02146833View on ClinicalTrials.gov

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 1, 2016

Study Completion Date

April 1, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Selinexor

Comparison of different dosages and dosing schedules of drug.

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Karyopharm Therapeutics Inc

INDUSTRY